Holen Sie sich die Stockscreener-App
2.60
4.00%
0.10
Schlusskurs vom Vortag:
$2.50
Offen:
$2.43
24-Stunden-Volumen:
16,130
Relative Volume:
0.18
Marktkapitalisierung:
$6.29M
Einnahmen:
$5.31M
Nettoeinkommen (Verlust:
$-2.90M
KGV:
-1.7503
EPS:
-1.4855
Netto-Cashflow:
$-1.18M
1W Leistung:
+19.54%
1M Leistung:
+28.77%
6M Leistung:
-36.89%
1J Leistung:
-12.31%
1-Tages-Spanne:
$2.43
$2.60
1-Wochen-Bereich:
$1.07
$2.70
52-Wochen-Spanne:
$1.07
$15.60
Bionexus Gene Lab Corp Stock (BGLC) Company Profile
Firmenname
Bionexus Gene Lab Corp
Sektor
Branche
Telefon
1-307-241-6898
Adresse
10-2 TOWER B, VERTICAL BUSINESS SUITE,, KUALA LUMPUR
Compare BGLC vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BGLC
BioNexus Gene Lab Corp Common stock
|
0.343 | 201.51M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Bionexus Gene Lab Corp Aktie (BGLC) Neueste Nachrichten
12 Industrials Stocks Moving In Thursday's Pre-Market Session - Benzinga
BioNexus Gene Lab Corp (BGLC) Slips 4.1%: Testing Key Support at $2.09Elliott Wave Entry - newsline.com
BioNexus Gene Lab Calls for Malaysia–China Biotech Co-Development and Precision Healthcare Collaboration 1 - Minichart
BioNexus Gene Lab Urges Malaysia–China Co-Development of Biotech Platforms After Kuala Lumpur Forum - TradingView
BioNexus Gene Lab (Nasdaq: BGLC) pushes Malaysia–China biotech co-development model - Stock Titan
BioNexus Gene Lab Corp (BGLC) Declines 8.33% as Stock Approaches Key SupportHigh Beta Stocks - The Legal Advocate
BioNexus Gene Lab Corp (BGLC) Slides 4.17% as Support Level Nears – Key Levels to WatchRating Change - newsline.com
BioNexus Gene Lab Corp (BGLC) Slides 6.25%: Key Support Zone Under ScrutinyCash Flow Strong Stocks - The Legal Advocate
BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Collaboration Focused on Joint Development - geneonline.com
BioNexus Gene Lab Corp. Calls for Malaysia–China - GlobeNewswire
Turning Malaysia into a bridge for China’s biotech ambitions - Stock Titan
BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle - Bez Kabli
12 Industrials Stocks Moving In Wednesday's After-Market Session - Sahm
BioNexus Gene Lab Corp (BGLC) Surges 8.44%: Testing Key Resistance at $2.30Channel Breakout - The Legal Advocate
BioNexus Gene Lab (BGLC) Extends Decline, Tests Key Support at $1.92Crowd Entry Signals - Newser
BioNexus Gene Lab Corp 1Q 2026: Revenue $22.84K, EPS ($0.23) — 10-Q Summary - TradingView
BioNexus Gene Lab Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] BioNexus Gene Lab Corp Quarterly Earnings Report - Stock Titan
BGLC | BioNexus Gene Lab Corp Insider Trading - Quiver Quantitative
TradingKey - TradingKey
Is BioNexus Lab (BGLC) stock fading in strength |Community Buy Alerts - newser.com
BioNexus Lab (BGLC) Risk Reward Ratio | BioNexus Gene Lab posts strong revenue, net lossCertified Trade Ideas - Xã Vĩnh Công
BioNexus Gene Lab: Chemical Raw Materials & Genomic Screening Business Overview, Growth Strategies, and Market Insights 19233034 - Minichart
BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61) - TradingView
[10-K] BioNexus Gene Lab Corp Files Annual Report - Stock Titan
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Analyst Upgrade: Will BioNexus Gene Lab Corp stock recover after earningsPortfolio Profit Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioNexus Gene Lab Corp. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Will BioNexus Lab (BGLC) Stock Grow in 2026 | Price at $2.15, Down 4.41%Put Support - newsline.com
Ideas Watch: Does BioNexus Gene Lab Corp stock reflect fundamentalsShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
BGLC Stock Price, Quote & Chart | BIONEXUS GENE LAB CORP (NASDAQ:BGLC) - ChartMill
How is BioNexus Lab (BGLC) Stock performing in 2026 | Price at $2.30, Up 1.71%Weak Sell Signals - The Legal Advocate
Can BioNexus Lab (BGLC) Stock Go Higher | Price at $2.23, Up 0.98%Bollinger Expansion - newsline.com
BGLC SEC FilingsBionexus Gene La 10-K, 10-Q, 8-K Forms - Stock Titan
[NT 10-K] BioNexus Gene Lab Corp SEC Filing - Stock Titan
12 Industrials Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Volume Recap: Can BioNexus Gene Lab Corp be the next market leader2026 Pullback Review & Stock Portfolio Risk Control - baoquankhu1.vn
Portfolio Update: Is BioNexus Gene Lab Corp in a consolidation phase2026 Sector Review & Daily Growth Stock Tips - baoquankhu1.vn
Will BioNexus Gene Lab Corp stock recover after earningsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
Aug Highlights: Does LTRY have declining or rising EPS2026 Intraday Action & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Tech Rally: Will BioNexus Gene Lab Corp outperform its industry peersPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
12 Industrials Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BioNexus Gene Lab (NASDAQ: BGLC) taps new CCO to drive Fidelion VitaGuard MRD commercialization - Stock Titan
BioNexus Gene Lab appoints commercial officer at Fidelion By Investing.com - Investing.com Nigeria
BioNexus Gene Lab appoints commercial officer at Fidelion - Investing.com India
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform - Bitget
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform - The Manila Times
BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics - Quiver Quantitative
Cancer relapse blood tests: Fidelion hires 15-year oncology diagnostics veteran - Stock Titan
12 Industrials Stocks Moving In Monday's Intraday Session - Sahm
Finanzdaten der Bionexus Gene Lab Corp-Aktie (BGLC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):